Medical/Pharmaceuticals
GORE® CARDIOFORM Septal Occluder Marks 10 Years of Improving Lives
After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. FLAGSTAFF, Ariz., Jan. 20, 2022 /PRNewswire/ -- W. L. Gore & Associates (Gore) today announced that the GORE® CARDIOFORM Septal Oc...
2022-01-20 10:17
2761
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive approval for provisional registration inAustralia GAITHERSBURG, Md., Jan. 20, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for seri...
2022-01-20 07:29
2088
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy
WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on thein-vivo gene replacement thera...
2022-01-19 22:30
2553
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets
JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provin...
2022-01-19 20:30
2454
Peijia Medical Obtained Exclusive License for JenaValve's Trilogy TAVR System for Treating AR in the Greater China Region
SUZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and wil...
2022-01-19 20:00
4518
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
* Purchase of Assets and Related Global Commercialization Rights for Oral 9- cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. * Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by Mutati...
2022-01-19 19:49
2462
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...
2022-01-19 08:30
2133
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in itsChina phase ...
2022-01-18 21:00
2326
CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market
LISHUI, China, Jan. 18, 2022 /PRNewswire/ -- CN Energy Group. Inc. (the "Company") today announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management ("O&M") agreement (the "Agreement") with HuaiNan JiaHe New Materials Co., Ltd. ("JiaHe") and JiaHe's acti...
2022-01-18 21:00
2522
Akeso's AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors
HONG KONG, Jan. 18, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announces that Ligufalimab (CD47 monoclonal antibody, research and development code: AK117), the novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody, research an...
2022-01-18 20:44
2829
MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation
HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for an important class B GPCR drug target, 8 Months After Program Initiation. Historically, the developm...
2022-01-18 17:17
2305
InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355
BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient inChina has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies, for th...
2022-01-18 14:51
2966
WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...
2022-01-18 10:50
2884
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules
SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli ...
2022-01-18 10:41
2932
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment ofRichard John Daly ("M...
2022-01-17 21:50
3300
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease
SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- On January 13, 2022, Green Valley ( Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (...
2022-01-17 14:29
1762
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in pati...
2022-01-17 09:04
1939
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin
TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc.
(NASDAQ: SXTC
2022-01-15 03:30
4562
I-Mab Announces Execution of Senior Management Team Share Purchase Plan
* The execution demonstrates senior management team's tremendous confidence in the Company's innovative globally competitive pipeline and long-term growth prospects SHANGHAI and GAITHERSBURG, MD., Jan. 14, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceut...
2022-01-14 21:00
7429
Leading E-commerce Logistics and Fulfillment Brand NextSmartShip Partners with B2B Medical E-commerce Giant LyncMed
SHENZHEN, China, Jan. 13, 2022 /PRNewswire/ -- NextSmartShip
2022-01-13 22:40
2560
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 308 media titles]
2026-10-27 13:40
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 297 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
38103
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
37523
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
36526
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
30492
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
30354